Art. -Nr.: HY-B1019

Sulpiride

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.28%
CAS. Nr.: 15676-16-1
Formel: C₁₅H₂₃N₃O₄S
Molecular Weight:341.43

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Sulpiride Chemical Structure

CAS. Nr.: 15676-16-1

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

D₂ Receptor

D₃ Receptor

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	560 nM Compound: Sulpiride	Antagonist activity at human dopamine D3 receptor expressed in CHO-K1 cells assessed as inhibition of dopamine-induced recruitment of beta-arrestin-2 after 90 mins by beta-galactosidase assay Antagonist activity at human dopamine D3 receptor expressed in CHO-K1 cells assessed as inhibition of dopamine-induced recruitment of beta-arrestin-2 after 90 mins by beta-galactosidase assay	[PMID: 21495689]
Sf21	IC₅₀	>1000 μM Compound: Sulpiride	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Sulpiride	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Dopamine, Alzheimer's, depression, Anxiety, Sprague-Dawley rats, NMRI mouse, Parkinson’s disease, psychosis, MCF-7/Adr, Breast cancer, Dexamethasone, Drug combination，MCF-7/Adr, Cancer stem-like cells (CSCs)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sulpiride (50 mg/kg; Subcutaneous injection; Single dose) can increase the dopamine level in Sprague-Dawley rats^[2].
Sulpiride (5-20 mg/kg; Intraperitoneal injection; Single dose) improves memory, but induces anxiety in Parkinson's disease (PD) mice at a dose of 20 mg/kg^[3].
Sulpiride (25-100 mg/kg; Oral gavage; Once daily for 18 days) can enhance the anti-tumor activity of dexamethasone (DEX) (HY-14648) (1 and 8 mg/kg) in combination with dexamethasone in nu/nu nude mice bearing MCF-7/Adr xenografts.Without significant toxicity to organs^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley rats model^[2]
Dosage:

50 mg/kg
Administration:

Subcutaneous injection (s.c.); Single dose.
Result:

Caused dopamine concentrations in the dialysates to roughly double.

Animal Model:

6-hydroxydopamine (6-OHDA) male NMRI mouse model of Parkinson’s disease (PD)^[3]
Dosage:

5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:

Intraperitoneal injection (i.p.); Single dose
Result:

Decreased %OAT (open-arm time) but had no significant effect on %OAE (open-arm entries) and locomotor activity.

Animal Model:

Female nu/nu nude mouse models of breast cancer bearing MCF-7/Adr xenografts^[4]
Dosage:

25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:

Oral gavage (p.o.); Once daily for 18 days. In combination with DEX (1 and 10 mg/kg; p.o.; Once daily for 18 days)
Result:

When used in combination with DEX (1 mg/kg) at 50 m/kg, enhanced the tumor suppression rate (14.4%).
When combined with DEX (8 mg/kg) at 25, 50, and 100 mg/kg, enhanced the tumor suppression rate by 30.2%, 27.55%, and 14.97%, respectively.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 15676-16-1
Appearance Solid
Molecular Weight 341.43
Formel C₁₅H₂₃N₃O₄S
Color White to off-white
SMILES

O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(N)=O)=CC=C2OC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All Bio/Physico-chemical AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Methods

Improved green and red GRAB sensors for monitoring dopaminergic activity in vivo. [Abstract]

2024 Apr;21(4):680-691. PMID: 38036855

Sulpiride purchased from MedChemExpress. Usage Cited in: Nat Methods. 2024 Apr;21(4):680-691. [Abstract]

Normalized fluorescence change in gDA3m to indicated compounds (1 μM). Sulpiride (Sulp), D2R antagonist. n = 3 wells with 500-600 cells per well.

Sulpiride purchased from MedChemExpress. Usage Cited in: Nat Methods. 2024 Apr;21(4):680-691. [Abstract]

Activation of endogenous D₂Rs by the D2-specific agonist quinpirole decreased the stimulus-evoked change in gDA3m fluorescence, reflecting presynaptic inhibition via D2 autoreceptors; this decrease was reversed by the addition of D₂R antagonist Sulpiride (Sulp), and adding the D₁R-specific antagonist SCH abolished the stimulation-evoked response.
Neuron

Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter. [Abstract]

2023 May 17;111(10):1626-1636.e6. PMID: 36917979
Mol Psychiatry

A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype. [Abstract]

2025 Dec 12. PMID: 41388144

Sulpiride purchased from MedChemExpress. Usage Cited in: Mol Psychiatry. 2025 Dec 12. [Abstract]

Peak frequency analysis of calcium traces retrieved from spontaneously active ALN and NGN2 neurons after 24 h treatment with DMSO (solvent control), 10 µM of Pramipexole dihydrochloride (DRD2 agonist) or 10 µM of Sulpiride (DRD2 antagonist).
Acta Pharmacol Sin

Single-dose methamphetamine administration impairs ORM retrieval in mice via excessive DA-mediated inhibition of PrLGlu activity. [Abstract]

2024 Nov;45(11):2253-2266. PMID: 38914676

Sulpiride purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2253-2266. [Abstract]

Experimental timeline and schematic of NOR test to examine the role of Sulpiride (D2R antagonist) on ORM retrieval in saline- and METH-treated mice. Saline or METH (2 mg/kg, i.p.) was injected 30 min before the test; simultaneously, saline or Sulpiride (0.25 μg/side) was microinfused bilaterally into PrL.

Sulpiride purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2253-2266. [Abstract]

Bilateral infusion of Sulpiride (0.25 μg/side) effectively reversed the ORM retrieval impairment. In addition, the exploration time of novel object C compared with familiar object A was not significantly different in the Saline + Sulpiride (0.25 μg/side) group, while PI was decreased compared with the Saline + Saline group.
J Headache Pain

Downregulation of neuronal DRD2 drives microglia synaptic pruning and results in cognitive deficits by promoting CCL2 release in a rat model of chronic migraine. [Abstract]

2026 Feb 9;27(1):39. PMID: 41663919
J Headache Pain

Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine. [Abstract]

2022 Aug 10;23(1):98. PMID: 35948867
Antioxidants (Basel)

Dopamine D2 Receptor Activation Blocks GluA2/ROS Positive Feedback Loop to Alienate Chronic-Migraine-Associated Pain Sensitization. [Abstract]

2024 Jun 14;13(6):725. PMID: 38929165
iScience

Thrombospondin1 mimics rapidly relieve depression via Shank3 dependent uncoupling between dopamine D1 and D2 receptors. [Abstract]

2023 Mar 22;26(4):106488. PMID: 37091229
J Neurosci

Potentiation of Nigra-Striatal Dopaminergic Projection Underpins Core Autism-Like Behaviors in Valproate-Exposed Mice. [Abstract]

2025 Sep 3;45(36):e0382252025. PMID: 40769723
Brain Res

Single administration of vitamin C produces rapid antidepressant-like effects in female mice: A possible role of dopamine D2 receptor signalling. [Abstract]

2026 Mar 15:1875:150181. PMID: 41577025
bioRxiv

Improved dual-color GRAB sensors for monitoring dopaminergic activity in vivo. [Abstract]

2023 Aug 25:2023.08.24.554559. PMID: 37662187

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (292.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9289 mL

14.6443 mL

29.2886 mL

5 mM

0.5858 mL

2.9289 mL

5.8577 mL

10 mM

0.2929 mL

1.4644 mL

2.9289 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rüther, E et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry vol. 32,4 (1999): 127-35. [Content Brief]

[2]. Jaworski, J N et al. Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. European journal of pharmacology vol. 418,3 (2001): 201-6. [Content Brief]

[3]. Zarrindast, Mohammad-Reza et al. Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis. Neurobiology of learning and memory vol. 186 (2021): 107538. [Content Brief]

[4]. Li, Jian et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta pharmacologica Sinica vol. 38,9 (2017): 1282-1296. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9289 mL	14.6443 mL	29.2886 mL	73.2215 mL
	5 mM	0.5858 mL	2.9289 mL	5.8577 mL	14.6443 mL
	10 mM	0.2929 mL	1.4644 mL	2.9289 mL	7.3221 mL
	15 mM	0.1953 mL	0.9763 mL	1.9526 mL	4.8814 mL
	20 mM	0.1464 mL	0.7322 mL	1.4644 mL	3.6611 mL
	25 mM	0.1172 mL	0.5858 mL	1.1715 mL	2.9289 mL
	30 mM	0.0976 mL	0.4881 mL	0.9763 mL	2.4407 mL
	40 mM	0.0732 mL	0.3661 mL	0.7322 mL	1.8305 mL
	50 mM	0.0586 mL	0.2929 mL	0.5858 mL	1.4644 mL
	60 mM	0.0488 mL	0.2441 mL	0.4881 mL	1.2204 mL
	80 mM	0.0366 mL	0.1831 mL	0.3661 mL	0.9153 mL
	100 mM	0.0293 mL	0.1464 mL	0.2929 mL	0.7322 mL

Keywords

Sulpiride

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sulpiride

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Dopamine Receptor Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Sulpiride

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Sulpiride Related Classifications

Art. -Nr.: HY-B1019